WT1 promotes epithelial-mesenchymal transition (EMT) via E-cadherin modulation and ERK1/2 signaling22, in addition to HOXA11 acting as a tumor promoter in EOC23 while TPM4 drives EMT, metastatic dissemination, and chemotherapy resistance24. Here, TPM4 is linked to neoplasm.